APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations.

APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

The company’s lead program, inhaled cyclosporine, is in Phase III for the prevention of chronic lung transplant rejection. For more information on the Phase III trial, visit the study website at www.cycliststudy.com

PRESS RELEASES

JANUARY 15, 2009
APT Pharmaceuticals Adds Stephen Aselage to Board of Directors

SEPTEMBER 30, 2008
APT Pharmaceuticals Secures $32 Million in Series B Financing

MEDIA COVERAGE

PALO ALTO /KGO ABC7 NEWS – JULY 8, 2008
APT supports Team Northern California at USA Transplant Games

START-UP MAGAZINE – MAY 2008
APT profiled in Start-Up Magazine